Puberty Blockers for Minors: When Evidence Shifts, Silence Is Not Neutral

Why I Asked South Australia to Pause New Prescriptions of Puberty Blockers for Minors

BY: Mark Neugebauer

12 January 2026

In recent months, I wrote to the South Australian Government, the Opposition, and several minor parties with a simple and, I believe, reasonable request:

That South Australia introduce a temporary, precautionary pause on new prescriptions of puberty blockers for minors, while explicitly safeguarding continuity of care for young people already receiving treatment.

This was not a protest letter. It was not a campaign. And it was not written from an ideological position.

It was written from a child-protection, evidence, and governance perspective, informed by international developments, South Australian legal obligations, and a concern for accountability in public health decision-making where irreversible decisions are made for children who lack full capacity to consent.

As we approach a state election, I believe it is appropriate to explain publicly why these concerns were raised, what was asked for, and what remains unanswered — not because of the electoral cycle itself, but because standards of accountability matter most when public trust is being actively sought.

What Prompted the Correspondence

Over the past several years, there has been a significant international shift in how paediatric gender medicine is approached — particularly regarding the prescription of puberty blockers to minors.

Jurisdictions often cited as leaders in public healthcare governance have moved toward greater caution, not greater certainty.

These include:

• The United Kingdom, following the Cass Review, which halted routine prescribing of puberty blockers for under-18s in the NHS and imposed indefinite restrictions due to what it described as an “unacceptable safety risk.”

• New Zealand, which has paused new prescriptions pending further evidence review.

• Nordic countries such as Sweden and Finland, which now restrict puberty blockers to research settings or exceptional cases.

• Queensland, which has paused new starts for minors in public services following governance and consent concerns.

These decisions do not abolish care for gender-distressed young people. Rather, they reflect an acknowledgement that:

• long-term evidence remains limited

• risks may be under-characterised

• consent and capacity issues are complex when minors are involved

• clinical governance requires strengthening

Given these developments, a reasonable question arises:

Why should South Australia continue unchanged while a national NHMRC review is underway precisely because evidence, risk, and long-term outcomes remain contested?

What I Actually Asked For

The request I made was deliberately narrow, balanced, and aligned with existing legal and ethical frameworks:

• A temporary pause on new prescriptions of puberty blockers for minors in state-funded services

• Explicit protection of continuity of care for children already receiving treatment

• An independent review of South Australian practices, including consent, governance, and oversight

• Transparent reporting of treatment numbers, outcomes, and adverse events

• Clear public communication to families and clinicians explaining the scope and purpose of the pause

This approach mirrors what several other jurisdictions have already implemented. It does not stigmatise vulnerable young people, nor does it abandon care. It simply applies the precautionary principle in circumstances where uncertainty, institutional authority, and irreversible consequences intersect for children.

Why This Matters in South Australia

South Australia already recognises, in law, that children require heightened protection in medical decision-making because capacity, consent, and long-term consequences cannot be assumed.

Our legislative framework requires:

• careful assessment of capacity to consent

• appropriate parental or guardian involvement

• protection of children from harm across service systems

• proportional governance where long-term consequences are involved

Yet South Australia’s Statewide Gender Diversity Model of Care has not been publicly reviewed in light of the substantial international developments of recent years.

A temporary pause on new starts would allow time to ensure that practice, evidence, and legal obligations remain aligned, without destabilising current patients.

What Remains Unanswered

I received an initial response from the Minister for Health acknowledging the existence of the national NHMRC review.

What has not yet been addressed are several substantive questions, including:

• Whether South Australia will adopt interim precautionary measures while that review is underway

• Whether SA Health has conducted its own audit or safety review of paediatric gender services

• How clinical consistency and oversight are being ensured in the absence of updated guidelines

• Whether long-term outcome data and adverse events are being systematically collected and published

• How South Australia is ensuring alignment with current international evidence, rather than relying solely on older domestic guidance

A detailed follow-up letter was sent seeking clarification on these points. At the time of writing, no further response has been received.

I make no claims about motive or intent .But silence on substantive questions is not neutral, because when institutional power, unresolved uncertainty, and irreversible interventions coincide, the absence of explanation itself becomes an ethical position.

Why This Correspondence Is Already Public

The correspondence referenced in this article has already been made publicly available as part of my broader commitment to transparency and good-faith civic engagement.

These letters document an attempt to engage respectfully with elected representatives across government, opposition, and minor parties on a matter involving children, medical uncertainty, and public accountability.

They show what was asked, how it was framed, and where clarification has, so far, not been provided.

I am not asking readers to agree with every concern raised. I am simply inviting them to assess the dialogue for themselves.

In a democratic system, public trust depends not only on outcomes, but on the willingness of institutions to explain their reasoning, especially when evidence is evolving and decisions carry long-term consequences.

A Closing Thought as We Approach an Election

Elections are not only about promises. They are about standards.

How governments respond to uncertainty, particularly when children are involved — tells us much about their approach to power, precaution, and accountability.

My position remains unchanged:

• Not to end care

• Not to stigmatise vulnerable young people

• But to ensure that when irreversible decisions are made on behalf of children, they are made with the highest possible standard of evidence, transparency, and humility

Frequently Asked Questions

Are you opposed to care for gender-diverse young people?

No. Nothing in my correspondence calls for withdrawal of care or abandonment of young people experiencing gender distress. My request explicitly protects continuity of care for children already receiving treatment.

The concern relates to new prescriptions in the context of unresolved evidence — not to counselling, psychological support, or compassion.

Isn’t this importing overseas “culture wars” into Australia?

The international developments referenced are health-system decisions, not ideological campaigns, and they are best understood as institutional recalibration rather than political alignment.

Australia routinely considers international evidence when updating clinical practice. Ignoring it because it is politically uncomfortable would itself be ideological.

Don’t experts already support current practice?

Some do. Others do not.

The existence of a national NHMRC review reflects precisely this reality: evidence is contested, long-term data is limited, and governance standards vary.

When expert opinion diverges, precaution and transparency become more important, not less.

Wouldn’t a pause harm trans-identified children?

A pause on new prescriptions, combined with protection for existing patients, is designed to minimise harm on all sides.

It recognises two risks that must be held together:

• potential harms from insufficiently studied medical intervention

• harms from abrupt withdrawal of care

Several jurisdictions have adopted this balanced approach to avoid false either-or framing.

Why raise this during an election period?

Elections are moments of public accountability.

This issue was raised across the political spectrum because it is not about party politics. It is about whether governments are willing to explain how they are responding to evolving evidence when children are involved.

Timing does not change the substance of the questions.

Are you accusing the government of wrongdoing?

No.

I make no claims of bad faith or malice. My concern is structural and procedural: whether current practice remains aligned with evidence, legal obligations, and child-protection standards.

Asking for explanation and review is not an accusation, it is a democratic norm.

What would satisfy you at this point?

At minimum:

• a clear explanation of South Australia’s current approach

• transparency about data collection and clinical governance

• an outline of how interim risks are being managed while the national review is underway

Even disagreement would be preferable to silence.

Primary Source Documents

The correspondence referenced in this article is available as primary source material for transparency and context:

• Initial correspondence to the South Australian Government - https://drive.proton.me/urls/FRFCSZJ1P4#UCmPzZvOy17B

• Response from Minister for Health and Wellbeing - https://drive.proton.me/urls/XYM5N7WRJ8#zxeIyMBpvbjT

• Follow-up correspondence seeking clarification - https://drive.proton.me/urls/P72AMQQTXC#b9QMaxCti5J2

These documents reflect my thinking at the time they were written and are provided so readers can assess the dialogue for themselves.